scholarly journals RELEVANCE OF DIAGNOSTICS AND TREATMENT OF BREAST CANCER IN MEN

2021 ◽  
pp. 3-7
Author(s):  
L. Alimkhodjaeva ◽  
M. Norbekova
Keyword(s):  
Breast Cancer ◽  
Genetic Testing ◽  
Adjuvant Chemotherapy ◽  
Prognostic Value ◽  
Molecular Subtypes ◽  
Breast Tumors ◽  
Malignant Breast ◽  
Molecular Assessment ◽  
Breast Cancer In Men

Breast cancer in men is a rare disease, accounting for approximately 0.1% of all malignant breast tumors in men and from 0.6% to 1% of all malignant breast tumors. The incidence of breast cancer in men increases with age for unknown reasons: the average age of men at the time of diagnosis is 67 years, compared with women, whose similar indicator is 57 years. Despite advances in the diagnostics and treatment of breast cancer in women, understanding and strategy for the treatment of breast cancer in men are limited and generally extrapolated from existing knowledge about breast cancer in women. In particular, the molecular subtypes of breast cancer in men have not been studied, although these subtypes have been associated with both biological and clinical features of breast cancer in women. It has been proven that molecular subtypes have an important prognostic value in breast cancer in women. Molecular assessment of tumors plays a significant role in the 22 prescriptions of adjuvant chemotherapy, and therefore the role of genetic testing increases.

scholarly journals Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging at 7T for Breast Cancer Diagnosis and Characterization

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3763
Author(s):  
R. Elena Ochoa-Albiztegui ◽  
Varadan Sevilimedu ◽  
Joao V. Horvat ◽  
Sunitha B. Thakur ◽  
Thomas H. Helbich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Molecular Subtypes ◽  
Breast Cancer Diagnosis ◽  
Breast Tumors ◽  
Resonance Imaging ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced ◽  
Malignant Breast

The purpose of this study was to investigate whether ultra-high-field dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the breast at 7T using quantitative pharmacokinetic (PK) analysis can differentiate between benign and malignant breast tumors for improved breast cancer diagnosis and to predict molecular subtypes, histologic grade, and proliferation rate in breast cancer. In this prospective study, 37 patients with 43 lesions suspicious on mammography or ultrasound underwent bilateral DCE-MRI of the breast at 7T. PK parameters (KTrans, kep, Ve) were evaluated with two region of interest (ROI) approaches (2D whole-tumor ROI or 2D 10 mm standardized ROI) manually drawn by two readers (senior reader, R1, and R2) independently. Histopathology served as the reference standard. PK parameters differentiated benign and malignant lesions (n = 16, 27, respectively) with good accuracy (AUCs = 0.655–0.762). The addition of quantitative PK analysis to subjective BI-RADS classification improved breast cancer detection from 88.4% to 97.7% for R1 and 86.04% to 97.67% for R2. Different ROI approaches did not influence diagnostic accuracy for both readers. Except for KTrans for whole-tumor ROI for R2, none of the PK parameters were valuable to predict molecular subtypes, histologic grade, or proliferation rate in breast cancer. In conclusion, PK-enhanced BI-RADS is promising for the noninvasive differentiation of benign and malignant breast tumors.

scholarly journals Expression analisis of the ITSN2 and TKS5 mRNA isoforms in human malignant breast tumors

2018 ◽  
Vol 16 (1) ◽  
pp. 20-27
Author(s):  
S. V. Kropyvko ◽  
L. O. Tsyba ◽  
O. V. Novokhatska ◽  
L. A. Syvak ◽  
T. Ye. Tarasenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Expression Analysis ◽  
Rna Isolation ◽  
Breast Tumors ◽  
Quantitative Real Time Pcr ◽  
Mrna Isoforms ◽  
Extensive Experience ◽  
Great Progress ◽  
Malignant Breast ◽  
The Many

Aim. Despite the great progress in cancer treating, the breast cancer remains lethal in 15 % cases. Regardless of the many years of research and extensive experience in the treatment of this type of cancer, one of the main problems in diagnosis and therapy is its high clinical and genetic heterogeneity. Thereby the identification of markers for personalized treatment of patients is still an actual issue. Methods. Collection of clinical material, RNA isolation, and expression analysis of ITSN2 and TKS5 isoforms using quantitative real time PCR with fluorescence-labeled probes. Results. We have found that ITSN2-S expression is reliably reduced in HER2/neu-positive tumors with poor prognosis. There were no significant differences in the expression of ITSN2-L and TKS5-L in the analyzed samples. Conclusions. These studies have demonstrated the possible use of ITSN2 short isoform (ITSN2-S) as a prognostic marker for breast cancer. Keywords: breast cancer, ITSN2, TKS5, expression analysis.

scholarly journals Primary breast lymphoma: a case report and review of the literature

2017 ◽  
Vol 7 (3) ◽  
Author(s):  
Kamal E.H. Mohamed ◽  
Rusha A.E. Ali
Keyword(s):  
Breast Cancer ◽  
Rare Case ◽  
Breast Tumors ◽  
Review Of The Literature ◽  
Primary Breast Lymphoma ◽  
Breast Lymphoma ◽  
First Case ◽  
High Prevalence ◽  
Malignant Breast ◽  
Hodgkin's Lymphomas

Primary breast lymphoma (PBL) represents 0.04-0.5% of all malignant breast tumors, <1% of all patients with non-Hodgkin’s lymphomas and 1.7-2.2% of all patients with extra nodal lymphomas. Despite the high prevalence of breast cancer, primary breast lymphoma is very rare. We report a rare case of PBL, successfully treated with surgery, chemotherapy and radiotherapy. This is the first case of PBL to be reported from Sudan to our knowledge.

scholarly journals Role of quantitative analysis of T2 relaxation time in differentiating benign from malignant breast lesions

2018 ◽  
Vol 46 (5) ◽  
pp. 1928-1935 ◽  
Author(s):  
Li Liu ◽  
Bo Yin ◽  
Kawai Shek ◽  
Daoying Geng ◽  
Yiping Lu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Relaxation Time ◽  
Quantitative Analysis ◽  
Breast Lesions ◽  
T2 Relaxation Time ◽  
T2 Relaxation ◽  
Malignant Breast ◽  
Mri Diagnosis ◽  
Malignant Lesions

Objective To investigate the role of quantitative analysis of T2 relaxation time in the magnetic resonance imaging (MRI) diagnosis of breast cancer. Methods The study enrolled patients with clinical breast masses who were examined using MRI at eight different echo times. The differences in T2 relaxation time of benign and malignant breast lesions were analysed. Results A total of 67 patients (67 breast lesions: 46 malignant, 21 benign) were examined. The mean ± SD T2 relaxation time was significantly lower in the 46 malignant lesions compared with the 21 benign lesions (82.69 ± 15.37 ms versus 95.48 ± 26.51 ms, respectively). The area under the curve was 0.731. Using 79.52 ms as the cut-off between benign and malignant breast lesions, a sensitivity of 85.7% and a specificity of 58.7% were obtained. Conclusions There was a significant difference in T2 relaxation time between benign and malignant breast lesions. The specificity of using T2 relaxation time alone for the differentiation of benign from malignant lesions was not high, but it could constitute a new adjunct in the MRI diagnosis of breast cancer.

Experience in performing organ-preserving and reconstructive plastic surgeries for malignant breast tumors at the Regional Clinical Center of Oncology in Khabarovsk

2021 ◽  
Vol 87 (1) ◽  
pp. 32-36
Author(s):  
A.A. Chernyayeva ◽  
◽  
A.S. Zenyukov ◽  
S.M. Korneyev ◽  
Ye.G. Lokalov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Local Recurrence ◽  
Clinical Oncology ◽  
Breast Tumors ◽  
Clinical Center ◽  
Malignant Breast ◽  
Oncology Center ◽  
Reconstructive Plastic

The article presents the experience of the Oncology department No. 1 of the Regional Clinical Oncology Center in Khabarovsk in performing organ-preserving and reconstructive plastic surgeries for breast cancer in the period 2014–2019. An assessment was made of the incidence of local recurrence or distant progression of the disease, as well as risk factors for their occurrence

The Role of Early Growth Response 1 in the Prognostic Value and Cell Migration of Breast Cancer

2021 ◽  
Author(s):  
Leiyu Hao ◽  
Fengru Huang ◽  
Xinqian Yu ◽  
Bujie Xu ◽  
Yan Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Migration ◽  
Protein Expression ◽  
Prognostic Value ◽  
Growth Response ◽  
Expression Patterns ◽  
Early Growth ◽  
The Cancer Genome Atlas ◽  
Early Growth Response

Abstract Background: Early growth response family members (EGRs), EGR1-4, have increasingly attracted attention in multiple cancers. However, the exact expression patterns and prognostic values of EGRs in the progress of breast cancer (BRCA) remain largely unknown. Methods: The mRNA expression and prognostic characteristics of EGRs were examined by the Cancer Genome Atlas (TCGA), Oncomine and Kaplan-Meier plotter. Enrichment analyses were conducted based on protein-protein interaction (PPI) network. The Tumor Immune Estimation Resource (TIMER) database and MethSurv were further explored. The protein expression level of EGR1 and cell migration were measured by Western blotting, immunohistochemistry, wound-healing assay and Boyden chamber assay in BRCA. Results: The transcriptional levels of EGR1/2/3 displayed significantly low expression in BRCA compared to that in normal tissues, while EGR4 was shown adverse expression pattern. Survival analysis revealed up-regulated EGR1-4 were remarkably associated with favorable relapse-free survival (RFS). A close correlation with specific tumor-infiltrating immune cells (TIICs) and several CpG sites of EGRs were exhibited. Immunohistochemistry assays showed that the protein expression of EGR1 was remarkably downregulated in BRCA compared to that in paracancerous tissues. Cell migration of MCF10A cells was increased after the silence of EGR1 by siRNA transfection.Conclusions: This study provides a novel insight to the role of EGR1 in the prognostic value and cell migration of BRCA.

Sign in / Sign up

Export Citation Format

Share Document